Different Therapeutic Strategies in 2 Young Patients with Advanced ALK-Rearranged Lung Adenocarcinoma: “The Light at the End of the Tunnel”
Malignant pleural effusion represents a prognostic negative factor on survival conferring stage IV disease. The median of survival is 5 months and a 5-year survival of about 3%. We describe the therapeutic success obtained from different strategies in anaplastic lymphoma kinase (ALK) inhibitors in 2...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Karger Publishers
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/a25798b70e3548b9b36e29ee8da2a987 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|